Cristiane Metran-Nascente1, Ivan Yeung2, Douglass C Vines2, Ur Metser3, Neesha C Dhani1, David Green2, Michael Milosevic2, David Jaffray2, David W Hedley4. 1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 2. Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and. 3. Department of Medical Imaging, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada david.hedley@uhn.ca.
Abstract
UNLABELLED: Pancreatic cancers are thought to be unusually hypoxic, which might sensitize them to drugs that are activated under hypoxic conditions. In order to develop this idea in the clinic, a minimally invasive technique for measuring the oxygenation status of pancreatic cancers is needed. METHODS: We tested the potential for minimally invasive imaging of hypoxia in pancreatic cancer patients, using the 2-nitroimidazole PET tracer (18)F-fluoroazomycin arabinoside (or (18)F-1-α-D-[5-fluoro-5-deoxyarabinofuranosyl]-2-nitroimidazole [(18)F-FAZA]). Dynamic and static scans were obtained in 21 patients with either locally advanced or metastatic disease. The hypoxic fraction was determined in the 2-h static scans as the percentage of voxels with SUVs more than 3 SDs from the mean values obtained for skeletal muscle. RESULTS: Hypoxia was detected in 15 of 20 evaluable patients, with the hypoxic fraction ranging from less than 5% to greater than 50%. Compartmental analysis of the dynamic scans allowed us to approximate the tumor perfusion as mL/min/g of tissue, a value that is independent of the extent of hypoxia derived from tracer uptake in the 2-h static scan. There was no significant correlation between tumor perfusion and hypoxia; nor did we see an association between tumor volume and hypoxia. CONCLUSION: Although pancreatic cancers can be highly hypoxic, a substantial proportion appears to be well oxygenated. Therefore, we suggest that a minimally invasive technique such as the one described in this study be used for patient stratification in future clinical trials of hypoxia-targeting agents.
UNLABELLED: Pancreatic cancers are thought to be unusually hypoxic, which might sensitize them to drugs that are activated under hypoxic conditions. In order to develop this idea in the clinic, a minimally invasive technique for measuring the oxygenation status of pancreatic cancers is needed. METHODS: We tested the potential for minimally invasive imaging of hypoxia in pancreatic cancerpatients, using the 2-nitroimidazole PET tracer (18)F-fluoroazomycin arabinoside (or (18)F-1-α-D-[5-fluoro-5-deoxyarabinofuranosyl]-2-nitroimidazole [(18)F-FAZA]). Dynamic and static scans were obtained in 21 patients with either locally advanced or metastatic disease. The hypoxic fraction was determined in the 2-h static scans as the percentage of voxels with SUVs more than 3 SDs from the mean values obtained for skeletal muscle. RESULTS:Hypoxia was detected in 15 of 20 evaluable patients, with the hypoxic fraction ranging from less than 5% to greater than 50%. Compartmental analysis of the dynamic scans allowed us to approximate the tumor perfusion as mL/min/g of tissue, a value that is independent of the extent of hypoxia derived from tracer uptake in the 2-h static scan. There was no significant correlation between tumor perfusion and hypoxia; nor did we see an association between tumor volume and hypoxia. CONCLUSION: Although pancreatic cancers can be highly hypoxic, a substantial proportion appears to be well oxygenated. Therefore, we suggest that a minimally invasive technique such as the one described in this study be used for patient stratification in future clinical trials of hypoxia-targeting agents.
Authors: Shingo Matsumoto; Shun Kishimoto; Keita Saito; Yoichi Takakusagi; Jeeva P Munasinghe; Nallathamby Devasahayam; Charles P Hart; Robert J Gillies; James B Mitchell; Murali C Krishna Journal: Cancer Res Date: 2018-05-23 Impact factor: 12.701
Authors: Edward Taylor; Jennifer Gottwald; Ivan Yeung; Harald Keller; Michael Milosevic; Neesha C Dhani; Iram Siddiqui; David W Hedley; David A Jaffray Journal: EJNMMI Res Date: 2017-12-22 Impact factor: 3.138
Authors: Carla Hajj; James Russell; Charles P Hart; Karyn A Goodman; Maeve A Lowery; Adriana Haimovitz-Friedman; Joseph O Deasy; John L Humm Journal: Transl Oncol Date: 2017-07-31 Impact factor: 4.243
Authors: Milan Grkovski; Louise Fanchon; Naga Vara Kishore Pillarsetty; James Russell; John L Humm Journal: EJNMMI Res Date: 2018-06-18 Impact factor: 3.138
Authors: Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès Journal: Int J Mol Sci Date: 2021-06-15 Impact factor: 5.923